Ecor1 Capital, Llc - Net Worth and Insider Trading

Ecor1 Capital, Llc Net Worth

The estimated net worth of Ecor1 Capital, Llc is at least $600 Million dollars as of 2024-11-05. Ecor1 Capital, Llc is the 10% Owner of Zymeworks Inc and owns about 13,437,473 shares of Zymeworks Inc (ZYME) stock worth over $198 Million. Ecor1 Capital, Llc is the 10% Owner of Prothena Corp PLC and owns about 11,584,280 shares of Prothena Corp PLC (PRTA) stock worth over $192 Million. Ecor1 Capital, Llc is also the 10% Owner of AnaptysBio Inc and owns about 7,794,996 shares of AnaptysBio Inc (ANAB) stock worth over $152 Million. Besides these, Ecor1 Capital, Llc also holds Akouos Inc (AKUS) , Voyager Therapeutics Inc (VYGR) , Surface Oncology Inc (SURF) , Corvus Pharmaceuticals Inc (CRVS) , Odonate Inc (ODTC) . Details can be seen in Ecor1 Capital, Llc's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ecor1 Capital, Llc has not made any transactions after 2024-08-14 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Ecor1 Capital, Llc

Ecor1 Capital, Llc Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ecor1 Capital, Llc owns 17 companies in total, including Surface Oncology Inc (SURF) , Panacea Acquisition Corp (PANA.U) , and Akouos Inc (AKUS) among others .

Click here to see the complete history of Ecor1 Capital, Llc’s form 4 insider trades.

Insider Ownership Summary of Ecor1 Capital, Llc

Ticker	Comapny	Transaction Date	Type of Owner
SURF	Surface Oncology Inc	2020-09-01	10 percent owner
PANA.U	Panacea Acquisition Corp	2020-07-06	director & 10 percent owner
AKUS	Akouos Inc	2020-06-30	10 percent owner
		2022-05-05	10 percent owner
		2015-06-26	10 percent owner
		2014-05-22	10 percent owner
		2024-08-14	10 percent owner
		2021-10-01	10 percent owner
		2023-01-11	10 percent owner
		2021-12-10	10 percent owner
		2023-02-19	director
		2023-04-28	director & 10 percent owner
		2023-01-06	10 percent owner
		2023-06-16	10 percent owner
		2023-05-26	10 percent owner
		2023-07-27	10 percent owner
		2023-10-13	10 percent owner

Ecor1 Capital, Llc Latest Holdings Summary

Ecor1 Capital, Llc currently owns a total of 8 stocks. Among these stocks, Ecor1 Capital, Llc owns 13,437,473 shares of Zymeworks Inc (ZYME) as of June 16, 2023, with a value of $198 Million and a weighting of 33.09%. Ecor1 Capital, Llc owns 11,584,280 shares of Prothena Corp PLC (PRTA) as of May 5, 2022, with a value of $192 Million and a weighting of 32.02%. Ecor1 Capital, Llc also owns 7,794,996 shares of AnaptysBio Inc (ANAB) as of August 14, 2024, with a value of $152 Million and a weighting of 25.3%. The other 5 stocks Akouos Inc (AKUS) , Voyager Therapeutics Inc (VYGR) , Surface Oncology Inc (SURF) , Corvus Pharmaceuticals Inc (CRVS) , Odonate Inc (ODTC) have a combined weighting of 9.59% among all his current holdings.

Latest Holdings of Ecor1 Capital, Llc

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
ZYME	Zymeworks Inc	2023-06-16	13,437,473	14.77	198,471,476
PRTA	Prothena Corp PLC	2022-05-05	11,584,280	16.58	192,067,362
ANAB	AnaptysBio Inc	2024-08-14	7,794,996	19.47	151,768,572
AKUS	Akouos Inc	2020-06-30	1,975,984	13.29	26,260,827
VYGR	Voyager Therapeutics Inc	2023-01-11	3,851,507	6.61	25,458,461
SURF	Surface Oncology Inc	2020-09-01	4,701,081	1.07	5,030,157
CRVS	Corvus Pharmaceuticals Inc	2021-10-01	81,077	9.25	749,962
ODTC	Odonate Inc	2021-12-10	0	17,050.00	0

Holding Weightings of Ecor1 Capital, Llc

Ecor1 Capital, Llc Form 4 Trading Tracker

According to the SEC Form 4 filings, Ecor1 Capital, Llc has made a total of 5 transactions in Zymeworks Inc (ZYME) over the past 5 years, including 5 buys and 0 sells. The most-recent trade in Zymeworks Inc is the acquisition of 3,350,000 shares on June 16, 2023, which cost Ecor1 Capital, Llc around $27 Million.

According to the SEC Form 4 filings, Ecor1 Capital, Llc has made a total of 8 transactions in Prothena Corp PLC (PRTA) over the past 5 years, including 7 buys and 1 sells. The most-recent trade in Prothena Corp PLC is the sale of 1,062,736 shares on May 5, 2022, which brought Ecor1 Capital, Llc around $31 Million.

According to the SEC Form 4 filings, Ecor1 Capital, Llc has made a total of 6 transactions in AnaptysBio Inc (ANAB) over the past 5 years, including 5 buys and 1 sells. The most-recent trade in AnaptysBio Inc is the acquisition of 273,972 shares on August 14, 2024, which cost Ecor1 Capital, Llc around $10 Million.

More details on Ecor1 Capital, Llc's insider transactions can be found in the Insider Trading History of Ecor1 Capital, Llc table.

Insider Trading History of Ecor1 Capital, Llc

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ecor1 Capital, Llc Trading Performance

GuruFocus tracks the stock performance after each of Ecor1 Capital, Llc's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ecor1 Capital, Llc is 6.57%. GuruFocus also compares Ecor1 Capital, Llc's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ecor1 Capital, Llc within 3 months outperforms 7 times out of 19 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ecor1 Capital, Llc's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ecor1 Capital, Llc

Average Return

Average return per transaction

Outperforming Transactions

14 out of 19 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-1.54
Relative Return to S&P 500(%)	-3.61

Ecor1 Capital, Llc Ownership Network

Ownership Network List of Ecor1 Capital, Llc

No Data

Ownership Network Relation of Ecor1 Capital, Llc

Ecor1 Capital, Llc Owned Company Details

What does Surface Oncology Inc do?

Who are the key executives at Surface Oncology Inc?

Ecor1 Capital, Llc is the 10 percent owner of Surface Oncology Inc. Other key executives at Surface Oncology Inc include Deputy GC Chandra Adams , Chief Medical Officer Alison Oneill , and See Remarks Jessica Fees .

Surface Oncology Inc (SURF) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Surface Oncology Inc (SURF). Other recent insider transactions involving Surface Oncology Inc (SURF) include a net sale of 16,713 shares made by Robert W. Ross , a net sale of 9,434 shares made by Jessica Fees , and a net sale of 7,042 shares made by Alison Oneill .

In summary, during the past 3 months, insiders sold 0 shares of Surface Oncology Inc (SURF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 37,090 shares of Surface Oncology Inc (SURF) were sold and 0 shares were bought by its insiders, resulting in a net sale of 37,090 shares.

Surface Oncology Inc (SURF)'s detailed insider trading history can be found in Insider Trading Tracker table.

Surface Oncology Inc Insider Transactions

No Available Data

What does Panacea Acquisition Corp do?

Who are the key executives at Panacea Acquisition Corp?

Ecor1 Capital, Llc is the director & 10 percent owner of Panacea Acquisition Corp. Other key executives at Panacea Acquisition Corp include director & 10 percent owner Ecor1 Capital Fund Qualified, L.p. , director & CEO and Chairman of the Board Oleg Nodelman , and director & 10 percent owner Ecor1 Capital Fund, L.p. .

Panacea Acquisition Corp (PANA.U) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Panacea Acquisition Corp (PANA.U) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Panacea Acquisition Corp (PANA.U) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Panacea Acquisition Corp (PANA.U)'s detailed insider trading history can be found in Insider Trading Tracker table.

Panacea Acquisition Corp Insider Transactions

No Available Data

What does Akouos Inc do?

Who are the key executives at Akouos Inc?

Ecor1 Capital, Llc is the 10 percent owner of Akouos Inc. Other key executives at Akouos Inc include 10 percent owner Kearny Acquisition Corp , 10 percent owner Lilly Eli & Co , and Chief Operating Officer Jennifer Anne Wellman .

Akouos Inc (AKUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Akouos Inc (AKUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Akouos Inc (AKUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Akouos Inc (AKUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Akouos Inc Insider Transactions

No Available Data

What does Prothena Corp PLC do?

Who are the key executives at Prothena Corp PLC?

Ecor1 Capital, Llc is the 10 percent owner of Prothena Corp PLC. Other key executives at Prothena Corp PLC include See Remarks Karin L Walker , Chief Operating Officer Brandon S. Smith , and Chief Regulatory Officer Carol D. Karp .

Prothena Corp PLC (PRTA) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Prothena Corp PLC (PRTA). Other recent insider transactions involving Prothena Corp PLC (PRTA) include a net sale of 45,000 shares made by Karin L Walker , a net sale of 40,000 shares made by Carol D. Karp , and a net sale of 25,000 shares made by Michael J Malecek .

In summary, during the past 3 months, insiders sold 0 shares of Prothena Corp PLC (PRTA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 321,333 shares of Prothena Corp PLC (PRTA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 321,333 shares.

Prothena Corp PLC (PRTA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Prothena Corp PLC Insider Transactions

No Available Data

What does Eiger BioPharmaceuticals Inc do?

Who are the key executives at Eiger BioPharmaceuticals Inc?

Ecor1 Capital, Llc is the 10 percent owner of Eiger BioPharmaceuticals Inc. Other key executives at Eiger BioPharmaceuticals Inc include 10 percent owner Richard A Kayne , 10 percent owner Leen Kawas , and Chief Business Officer Ingrid Choong .

Eiger BioPharmaceuticals Inc (EIGRQ) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Eiger BioPharmaceuticals Inc (EIGRQ). Other recent insider transactions involving Eiger BioPharmaceuticals Inc (EIGRQ) include a net purchase of 278,239 shares made by Richard A Kayne , and a net purchase of 24,332 shares made by Leen Kawas .

In summary, during the past 3 months, insiders sold 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Eiger BioPharmaceuticals Inc (EIGRQ) were sold and 10,086 shares were bought by its insiders, resulting in a net purchase of 10,086 shares.

Eiger BioPharmaceuticals Inc (EIGRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Eiger BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Genvec Inc do?

Who are the key executives at Genvec Inc?

Ecor1 Capital, Llc is the 10 percent owner of Genvec Inc. Other key executives at Genvec Inc include director & President and CEO Douglas J Swirsky , 10 percent owner Mmcap International Inc. Spc , and other: See Explanation of Responses Ecor1 Capital Fund Qualified, L.p. .

Genvec Inc (GNVC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Genvec Inc (GNVC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Genvec Inc (GNVC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Genvec Inc (GNVC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Genvec Inc Insider Transactions

No Available Data

What does AnaptysBio Inc do?

Who are the key executives at AnaptysBio Inc?

Ecor1 Capital, Llc is the 10 percent owner of AnaptysBio Inc. Other key executives at AnaptysBio Inc include Chief Medical Officer Paul F. Lizzul , General Counsel Eric J Loumeau , and Chief Financial Officer Dennis Mulroy .

AnaptysBio Inc (ANAB) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made 1 insider transaction in AnaptysBio Inc (ANAB) with a net purchase of 273,972. Other recent insider transactions involving AnaptysBio Inc (ANAB) include a net sale of 11,879 shares made by Paul F. Lizzul , a net sale of 26,687 shares made by Eric J Loumeau , and a net sale of 24,965 shares made by Dennis Mulroy .

In summary, during the past 3 months, insiders sold 30,440 shares of AnaptysBio Inc (ANAB) in total and bought 273,972 shares, with a net purchase of 243,532 shares. During the past 18 months, 233,237 shares of AnaptysBio Inc (ANAB) were sold and 273,972 shares were bought by its insiders, resulting in a net purchase of 40,735 shares.

AnaptysBio Inc (ANAB)'s detailed insider trading history can be found in Insider Trading Tracker table.

AnaptysBio Inc Insider Transactions

No Available Data

What does Corvus Pharmaceuticals Inc do?

Who are the key executives at Corvus Pharmaceuticals Inc?

Ecor1 Capital, Llc is the 10 percent owner of Corvus Pharmaceuticals Inc. Other key executives at Corvus Pharmaceuticals Inc include director & President and CEO Miller Richard A Md , See Remarks William Benton Jones , and Chief Financial Officer Leiv Lea .

Corvus Pharmaceuticals Inc (CRVS) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Corvus Pharmaceuticals Inc (CRVS). Other recent insider transactions involving Corvus Pharmaceuticals Inc (CRVS) include a net purchase of 577,634 shares made by Miller Richard A Md , a net purchase of 20,000 shares made by William Benton Jones , and a net purchase of 10,000 shares made by Linda S Grais .

In summary, during the past 3 months, insiders sold 0 shares of Corvus Pharmaceuticals Inc (CRVS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Corvus Pharmaceuticals Inc (CRVS) were sold and 607,634 shares were bought by its insiders, resulting in a net purchase of 607,634 shares.

Corvus Pharmaceuticals Inc (CRVS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Corvus Pharmaceuticals Inc Insider Transactions

No Available Data

What does Voyager Therapeutics Inc do?

Who are the key executives at Voyager Therapeutics Inc?

Ecor1 Capital, Llc is the 10 percent owner of Voyager Therapeutics Inc. Other key executives at Voyager Therapeutics Inc include Chief Legal Officer Sandell Jacquelyn Fahey , Chief Operating Officer Robin Swartz , and Chief Scientific Officer Todd Alfred Carter .

Voyager Therapeutics Inc (VYGR) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Voyager Therapeutics Inc (VYGR). Other recent insider transactions involving Voyager Therapeutics Inc (VYGR) include a net sale of 21,233 shares made by Todd Alfred Carter , a net sale of 7,866 shares made by Robin Swartz , and a net sale of 25,148 shares made by Alfred Sandrock .

In summary, during the past 3 months, insiders sold 5,999 shares of Voyager Therapeutics Inc (VYGR) in total and bought 0 shares, with a net sale of 5,999 shares. During the past 18 months, 77,577 shares of Voyager Therapeutics Inc (VYGR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 77,577 shares.

Voyager Therapeutics Inc (VYGR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Voyager Therapeutics Inc Insider Transactions

No Available Data

What does Odonate Inc do?

Who are the key executives at Odonate Inc?

Ecor1 Capital, Llc is the 10 percent owner of Odonate Inc. Other key executives at Odonate Inc include director & 10 percent owner Boxer Capital, Llc , director & 10 percent owner & Chief Executive Officer Kevin C Tang , and director & 10 percent owner Aaron I. Davis .

Odonate Inc (ODTC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Odonate Inc (ODTC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Odonate Inc (ODTC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Odonate Inc (ODTC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Odonate Inc Insider Transactions

No Available Data

What does Nuvation Bio Inc do?

Who are the key executives at Nuvation Bio Inc?

Ecor1 Capital, Llc is the director of Nuvation Bio Inc. Other key executives at Nuvation Bio Inc include Chief Medical Officer Dongfang Liu , 10 percent owner Omega Fund V Gp, L.p. , and 10 percent owner Omega Fund Iv Gp, L.p. .

Nuvation Bio Inc (NUVB) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Nuvation Bio Inc (NUVB). Other recent insider transactions involving Nuvation Bio Inc (NUVB) include a net purchase of 777,895 shares made by Xiangmin Cui , a net purchase of 5,313,100 shares made by Oleg Nodelman , and a net purchase of 172,189 shares made by Kim D Blickenstaff .

In summary, during the past 3 months, insiders sold 0 shares of Nuvation Bio Inc (NUVB) in total and bought 100,000 shares, with a net purchase of 100,000 shares. During the past 18 months, 0 shares of Nuvation Bio Inc (NUVB) were sold and 6,363,184 shares were bought by its insiders, resulting in a net purchase of 6,363,184 shares.

Nuvation Bio Inc (NUVB)'s detailed insider trading history can be found in Insider Trading Tracker table.

Nuvation Bio Inc Insider Transactions

No Available Data

What does Panacea Acquisition Corp II do?

Who are the key executives at Panacea Acquisition Corp II?

Ecor1 Capital, Llc is the director & 10 percent owner of Panacea Acquisition Corp II. Other key executives at Panacea Acquisition Corp II include director & 10 percent owner Ecor1 Capital Fund Qualified, L.p. , director & 10 percent owner Oleg Nodelman , and director & 10 percent owner Ecor1 Capital Fund, L.p. .

Panacea Acquisition Corp II (PANA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Panacea Acquisition Corp II (PANA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Panacea Acquisition Corp II (PANA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Panacea Acquisition Corp II (PANA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Panacea Acquisition Corp II Insider Transactions

No Available Data

What does Graphite Bio Inc do?

Who are the key executives at Graphite Bio Inc?

Ecor1 Capital, Llc is the 10 percent owner of Graphite Bio Inc. Other key executives at Graphite Bio Inc include 10 percent owner Samsara Biocapital, L.p. , CHIEF BUSINESS OFFICER Phil Gutry , and Chief Financial Officer Alethia Young .

Graphite Bio Inc (GRPH) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Graphite Bio Inc (GRPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Graphite Bio Inc (GRPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Graphite Bio Inc (GRPH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Graphite Bio Inc Insider Transactions

No Available Data

What does Zymeworks Inc do?

Who are the key executives at Zymeworks Inc?

Ecor1 Capital, Llc is the 10 percent owner of Zymeworks Inc. Other key executives at Zymeworks Inc include director & Chair & CEO Kenneth Galbraith , SVP & Chief Financial Officer Christopher Astle , and Chief Scientific Officer Paul Andrew Moore .

Zymeworks Inc (ZYME) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made 1 insider transaction in Zymeworks Inc (ZYME) with a net purchase of 3,350,000. Other recent insider transactions involving Zymeworks Inc (ZYME) include a net sale of 6,880 shares made by Christopher Astle , a net sale of 23,904 shares made by Kenneth Galbraith , and a net sale of 9,799 shares made by Paul Andrew Moore .

In summary, during the past 3 months, insiders sold 0 shares of Zymeworks Inc (ZYME) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 40,583 shares of Zymeworks Inc (ZYME) were sold and 3,350,000 shares were bought by its insiders, resulting in a net purchase of 3,309,417 shares.

Zymeworks Inc (ZYME)'s detailed insider trading history can be found in Insider Trading Tracker table.

Zymeworks Inc Insider Transactions

No Available Data

What does TScan Therapeutics Inc do?

Who are the key executives at TScan Therapeutics Inc?

Ecor1 Capital, Llc is the 10 percent owner of TScan Therapeutics Inc. Other key executives at TScan Therapeutics Inc include Chief Legal Officer Zoran Zdraveski , Chief Accounting Officer Leiden Dworak , and 10 percent owner Weston Nichols .

TScan Therapeutics Inc (TCRX) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in TScan Therapeutics Inc (TCRX). Other recent insider transactions involving TScan Therapeutics Inc (TCRX) include a net purchase of 20,000 shares made by Barbara Klencke , a net purchase of 67,027 shares made by Timothy J Barberich , and a net sale of 164,686 shares made by Zoran Zdraveski .

In summary, during the past 3 months, insiders sold 164,686 shares of TScan Therapeutics Inc (TCRX) in total and bought 15,000 shares, with a net sale of 149,686 shares. During the past 18 months, 190,086 shares of TScan Therapeutics Inc (TCRX) were sold and 87,027 shares were bought by its insiders, resulting in a net sale of 103,059 shares.

TScan Therapeutics Inc (TCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

TScan Therapeutics Inc Insider Transactions

No Available Data

What does Mersana Therapeutics Inc do?

Who are the key executives at Mersana Therapeutics Inc?

Ecor1 Capital, Llc is the 10 percent owner of Mersana Therapeutics Inc. Other key executives at Mersana Therapeutics Inc include SVP & Chief Development Officer Mohan Bala , Chief Legal Officer Alejandra Carvajal , and Sr. VP & Finance & Product stgy Brian Deschuytner .

Mersana Therapeutics Inc (MRSN) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Mersana Therapeutics Inc (MRSN). Other recent insider transactions involving Mersana Therapeutics Inc (MRSN) include a net sale of 20,914 shares made by Mohan Bala , a net sale of 24,096 shares made by Timothy B Lowinger , and a net sale of 23,014 shares made by Brian Deschuytner .

In summary, during the past 3 months, insiders sold 115,271 shares of Mersana Therapeutics Inc (MRSN) in total and bought 0 shares, with a net sale of 115,271 shares. During the past 18 months, 184,420 shares of Mersana Therapeutics Inc (MRSN) were sold and 0 shares were bought by its insiders, resulting in a net sale of 184,420 shares.

Mersana Therapeutics Inc (MRSN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Mersana Therapeutics Inc Insider Transactions

No Available Data

What does Tango Therapeutics Inc do?

Who are the key executives at Tango Therapeutics Inc?

Ecor1 Capital, Llc is the 10 percent owner of Tango Therapeutics Inc. Other key executives at Tango Therapeutics Inc include 10 percent owner Third Rock Ventures Iv, L.p. , other: See remarks Mva Investors, Llc , and See Remarks Douglas Barry .

Tango Therapeutics Inc (TNGX) Insider Trades Summary

Over the past 18 months, Ecor1 Capital, Llc made no insider transaction in Tango Therapeutics Inc (TNGX). Other recent insider transactions involving Tango Therapeutics Inc (TNGX) include a net sale of 2,504,900 shares made by Third Rock Ventures Iv, L.p. , a net purchase of 2,750,000 shares made by Boxer Capital, Llc , and a net sale of 584,731 shares made by Mva Investors, Llc .

In summary, during the past 3 months, insiders sold 2,135,400 shares of Tango Therapeutics Inc (TNGX) in total and bought 0 shares, with a net sale of 2,135,400 shares. During the past 18 months, 4,859,148 shares of Tango Therapeutics Inc (TNGX) were sold and 2,975,000 shares were bought by its insiders, resulting in a net sale of 1,884,148 shares.

Tango Therapeutics Inc (TNGX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tango Therapeutics Inc Insider Transactions

No Available Data

Ecor1 Capital, Llc Mailing Address

Above is the net worth, insider trading, and ownership report for Ecor1 Capital, Llc. You might contact Ecor1 Capital, Llc via mailing address: 357 Tehama Street #3, San Francisco Ca 94103.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.